生物制剂和靶向合成改善病情抗风湿药治疗类风湿关节炎在临床实践中的安全性:ARTIS项目结果
基于瑞典ARTIS登记库的全国性队列研究纳入2010年1月1日至2020年12月31日期间开始使用任何b/tsDMARD的20 117例类风湿关节炎患者,随访至2021年6月30日,比较各药物关键安全性结局的发生率。因不良事件停药率差异明显(利妥昔单抗每1000人年18至托法替尼57),严重不良事件差异少;巴瑞替尼或托法替尼的心血管事件和严重感染不比bDMARDs更频繁,但JAKi与更高的住院治疗带状疱疹发生率相关(对比依那西普的HR分别为3.82和4.00)。
要点
- 因不良事件停药率从利妥昔单抗的每1000人年18到托法替尼的57不等。
- 巴瑞替尼或托法替尼的心血管事件和严重感染发生率与bDMARDs相比无显著差异。
- JAKi与住院治疗带状疱疹发生率升高相关,对比依那西普HR为3.82和4.00。
核心结论
- ARTIS数据支持目前用于治疗RA的b/tsDMARDs具有可接受且大体相似的安全性,但在耐受性和特定感染风险方面存在差异。
研究设计与样本
- 全国性登记库队列研究,纳入瑞典2010年1月1日至2020年12月31日期间开始使用任何b/tsDMARD的所有RA患者,随访至2021年6月30日,共20 117例。
主要发现
- 因不良事件停药率每1000人年从利妥昔单抗18到托法替尼57不等。
- 巴瑞替尼或托法替尼与bDMARDs相比,心血管事件和一般严重感染的发生率未显著更高。
- JAKi与住院治疗带状疱疹发生率升高相关,对比依那西普的HR分别为3.82(95%CI 2.05至7.09)和4.00(95%CI 1.59至10.06)。
- 事件数少限制了一些比较,尤其是沙利鲁单抗和托法替尼。
局限性
- 事件数少限制了一些比较,尤其是沙利鲁单抗和托法替尼。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Longitudinal clinical registry-infrastructures such as Anti-Rheumatic Therapies in Sweden (ARTIS) allow simultaneous comparison of the safety of individual immunomodulatory drugs used in clinical practice, with consistent definitions of treatment cohorts, follow-up and outcomes. Our objective was to assess and compare incidence rates of key safety outcomes for individual targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) in rheumatoid arthritis (RA), updating previous reports and including newer treatments including Janus Kinase inhibitors (JAKi). METHODS: Nationwide register-based cohort study including all patients with RA in Sweden registered as starting any b/tsDMARD 1 January 2010 through 31 December 2020, followed until 30 June 2021 (N=20 117). The incidence rates of selected outcomes, identified through national healthcare registers, were compared between individual b/tsDMARDs, adjusted for confounding by demographics, RA disease characteristics and comorbidity. RESULTS: There were marked differences in treatment discontinuations due to adverse events (rates per 1000 person-years ranged from 18 on rituximab to 57 on tofacitinib), but few significant differences were observed for the serious adverse events under study. Neither cardiovascular events nor general serious infections were more frequent on baricitinib or tofacitinib versus bDMARDs, but JAKi were associated with higher rates of hospital-treated herpes zoster (HR vs etanercept, 3.82 (95% CI 2.05 to 7.09) and 4.00 (1.59 to 10.06)). Low number of events limited some comparisons, in particular for sarilumab and tofacitinib. CONCLUSION: Data from ARTIS supports that the b/tsDMARDs currently used to treat RA have acceptable and largely similar safety profiles, but differences exist in particular concerning tolerability and specific infection risks.
引用
- Frisell T, Bower H, Morin M, et al. Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Ann Rheum Dis. 2023. PMID: 36787994. doi:10.1136/ard-2022-223762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。